Cargando…

Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity

INTRODUCTION: Obesity and aging negatively affect the immune system and host defense mechanisms, increasing vulnerability to and worsening prognosis of infectious diseases, leading to vaccine failure. Our aim was to investigate the antibody response against severe acute respiratory syndrome coronavi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kara, Zehra, Akçin, Rüveyda, Demir, Ahmet Numan, Dinç, Harika Öykü, Kocazeybek, Bekir, Yumuk, Volkan Demirhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443995/
https://www.ncbi.nlm.nih.gov/pubmed/37231909
http://dx.doi.org/10.1159/000530315
_version_ 1785093956481056768
author Kara, Zehra
Akçin, Rüveyda
Demir, Ahmet Numan
Dinç, Harika Öykü
Kocazeybek, Bekir
Yumuk, Volkan Demirhan
author_facet Kara, Zehra
Akçin, Rüveyda
Demir, Ahmet Numan
Dinç, Harika Öykü
Kocazeybek, Bekir
Yumuk, Volkan Demirhan
author_sort Kara, Zehra
collection PubMed
description INTRODUCTION: Obesity and aging negatively affect the immune system and host defense mechanisms, increasing vulnerability to and worsening prognosis of infectious diseases, leading to vaccine failure. Our aim was to investigate the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antigens and the risk factors affecting antibody levels in elderly patients living with obesity (PwO) after inactive SARS-CoV-2 vaccine (CoronaVac) administration. METHODS: One hundred twenty-three consecutive elderly patients with obesity (age ≥65 years, body mass index [BMI] ≥30 kg/m(2)) and 47 adults with obesity (age 18–64 years, BMI ≥30 kg/m(2)) admitted between August and November 2021 were enrolled. Seventy-five nonobese elderly people (age ≥65 years, BMI 18.5–29.9 kg/m(2)) and 105 nonobese adults (age 18–64 years, BMI 18.5–29.9 kg/m(2)) were recruited from subjects who visited the Vaccination Unit. SARS-CoV-2 spike protein antibody titers were measured in patients with obesity and nonobese controls who received two doses of CoronaVac. RESULTS: SARS-CoV-2 levels of patients with obesity were found to be significantly lower than those of nonobese elderly individuals who had non-prior infection. There was no difference in SARS-CoV-2 levels between patients with obesity and nonobese individuals with prior infection. Age and SARS-CoV-2 level were found to be highly correlated in the correlation analysis in the group of elderly individuals (r: −0.184). In multivariate regression analysis, when SARS-CoV-2 immunoglobulin class G (IgG) was regressed on age, sex, BMI, type 2 diabetes mellitus, and hypertension (HT), HT was found to be an independent factor of the SARS-CoV-2 level (β: −2,730). CONCLUSION: In the non-prior infection group, elderly patients with obesity generated significantly reduced antibody titers against SARS-CoV-2 spike antigen after CoronaVac vaccine compared to nonobese people. It is anticipated that the results obtained will provide invaluable information about SARS-CoV-2 vaccination strategies in this vulnerable population. Antibody titers may be measured, and booster doses should be delivered accordingly in elderly PwO for optimal protection.
format Online
Article
Text
id pubmed-10443995
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-104439952023-08-23 Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity Kara, Zehra Akçin, Rüveyda Demir, Ahmet Numan Dinç, Harika Öykü Kocazeybek, Bekir Yumuk, Volkan Demirhan Obes Facts Research Article INTRODUCTION: Obesity and aging negatively affect the immune system and host defense mechanisms, increasing vulnerability to and worsening prognosis of infectious diseases, leading to vaccine failure. Our aim was to investigate the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antigens and the risk factors affecting antibody levels in elderly patients living with obesity (PwO) after inactive SARS-CoV-2 vaccine (CoronaVac) administration. METHODS: One hundred twenty-three consecutive elderly patients with obesity (age ≥65 years, body mass index [BMI] ≥30 kg/m(2)) and 47 adults with obesity (age 18–64 years, BMI ≥30 kg/m(2)) admitted between August and November 2021 were enrolled. Seventy-five nonobese elderly people (age ≥65 years, BMI 18.5–29.9 kg/m(2)) and 105 nonobese adults (age 18–64 years, BMI 18.5–29.9 kg/m(2)) were recruited from subjects who visited the Vaccination Unit. SARS-CoV-2 spike protein antibody titers were measured in patients with obesity and nonobese controls who received two doses of CoronaVac. RESULTS: SARS-CoV-2 levels of patients with obesity were found to be significantly lower than those of nonobese elderly individuals who had non-prior infection. There was no difference in SARS-CoV-2 levels between patients with obesity and nonobese individuals with prior infection. Age and SARS-CoV-2 level were found to be highly correlated in the correlation analysis in the group of elderly individuals (r: −0.184). In multivariate regression analysis, when SARS-CoV-2 immunoglobulin class G (IgG) was regressed on age, sex, BMI, type 2 diabetes mellitus, and hypertension (HT), HT was found to be an independent factor of the SARS-CoV-2 level (β: −2,730). CONCLUSION: In the non-prior infection group, elderly patients with obesity generated significantly reduced antibody titers against SARS-CoV-2 spike antigen after CoronaVac vaccine compared to nonobese people. It is anticipated that the results obtained will provide invaluable information about SARS-CoV-2 vaccination strategies in this vulnerable population. Antibody titers may be measured, and booster doses should be delivered accordingly in elderly PwO for optimal protection. S. Karger AG 2023-05-25 /pmc/articles/PMC10443995/ /pubmed/37231909 http://dx.doi.org/10.1159/000530315 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission
spellingShingle Research Article
Kara, Zehra
Akçin, Rüveyda
Demir, Ahmet Numan
Dinç, Harika Öykü
Kocazeybek, Bekir
Yumuk, Volkan Demirhan
Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity
title Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity
title_full Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity
title_fullStr Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity
title_full_unstemmed Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity
title_short Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity
title_sort antibody response to inactive sars-cov-2 vaccination in a cohort of elderly patients living with obesity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443995/
https://www.ncbi.nlm.nih.gov/pubmed/37231909
http://dx.doi.org/10.1159/000530315
work_keys_str_mv AT karazehra antibodyresponsetoinactivesarscov2vaccinationinacohortofelderlypatientslivingwithobesity
AT akcinruveyda antibodyresponsetoinactivesarscov2vaccinationinacohortofelderlypatientslivingwithobesity
AT demirahmetnuman antibodyresponsetoinactivesarscov2vaccinationinacohortofelderlypatientslivingwithobesity
AT dincharikaoyku antibodyresponsetoinactivesarscov2vaccinationinacohortofelderlypatientslivingwithobesity
AT kocazeybekbekir antibodyresponsetoinactivesarscov2vaccinationinacohortofelderlypatientslivingwithobesity
AT yumukvolkandemirhan antibodyresponsetoinactivesarscov2vaccinationinacohortofelderlypatientslivingwithobesity